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Pengambilan cebisan hati adalah kaedah terbaik di dalam rawatan pesakit Hepatitis C, 
terutamanya untuk pengelasan tahap fibrosis hati. Kami mengharapkan ujikaji ini 
memberikan maklumat perhubungan di antara paras serum biokimia didalam darah 
dengan tahap fibrosis hati. 
Kaedah 
Kami mengkaji pesakit Hepatitis C yang didiagnosis melalui, PCR dan darah mereka 
diambil untuk ujian biokimikal. Kami menganalisa 60 orang pesakit. Perbandingan 
fibrosis hati di buat dengan paras serum biokimikal yang mempunyai hubungan paling 
baik.8ebelas petunjuk biokimikal digunakan dan tahap fibrosis hatijuga dikaji. Tahap 
fibrosis di bahagika kepada: SO= tiada fibrosis, 81= sedikit fibrosis pada traks portal, 
82=fibrosis dikebanyakan traks portal dan fibrosis septa pendek, 83= fibrosis di 
kebanyakan traks portal dan sedikit fibrosis diantara portal, 84= fibrosis di kebanyakan 
traks portal dan semua portal mempunyai fibrosis dan sedikit fibrosis diantara portal dan 
sentral, 85= kebanyakan traks di antara portal dan sentral mempunyai fibrosis dan sedikit 
nodul,86= cirrhosis sarna ada sedikit atau spenuhnya. Analisa statistik dibuat dengan ' 
mann whitney U test dan lengkungan ROC. 
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Keputusan 
Nilai mean ALT,GMT, aldosterone, HDL dan albumin dengan tahap fibrosis rendah dan 
tinggi adalah masing-masing adalah 82 ± 4 and 125 ± 31, 47.5 ± 31 and 81± 25, 116.6 ± 
56 and 184 ± 43, 1.4 ± 0.3 and 0.9 ± 0.2 and, 42 ± 4 and 35 ± 3.2. Analisa kawasan 
bawah lengkungan ROC mempunyai ketepatan yang diguna pakai. 
Kesimpulan 
Kami mendapati serum biokimikal seperti tersebut diatas mempunyai hubungan yang 




Liver biopsy is a mandatory procedure in the management of patients with hepatitis C 
virus infection, especially for staging fibrosis. We aimed, in our cross sectional study, to 
assess the relation of the serum biochemical markers for the diagnosis of clinically 
significant fibrosis(inc1uding early stages). 
Method 
We assessed liver biopsy patients with detectable hepatitis C by PCR, for eligibility and 
took their blood sample for the biochemical test. The analysis was done on 60 patients. 
We devised a fibrosis index that included the most informative markers (combined 
With age and sex). Eleven serum markers were assessed as well as fibrosis stages: 80= 
no fibrosis, 81 =fibrous expansion of some portal tracts ± short fibrous septa, S2=fibrous 
expansion of most portal tracts ± short fibrous septa, 83= fibrous expansion of most 
portal areas with occasional portal to portal (PP) bridging, 84=fibrous expansion of 
portal areas with marked bridging ( PP as well as portal-central (PC), SS= marked 
bridging (pP and or PC) with occasional nodules (incomplete cirrhosis), 86= cirrhosis, 
probable or definite. Statistical analysis was done using mann whitney U test and receiver 
operating characteristics ( ROC) curves. 
xi 
RESULTS 
Mean value of ALT, GMT, aldosterone, HOL, and albumin with mild fibrosis and severe 
fibrosis, was 82±4and 125±31,47.5±31 and 81±25, 116.6±56and 184± 43,1.4± 
0.3 and 0.9 ± 0.2 and, 42 ± 4 and 35 ± 3.2, respectively with a significant difference 
between them was (p <0.05). The area under the operating receiver characteristics 
showed significant accuracy for each biochemical parameters. 
CONCLUSION 
We found positive correlation between the ALT, GMT, aldosterone, albumin and fibrosis 
stages on liver biopsy in hepatitis C patients. Serum biochemical markers have significant 




Worldwide, viral hepatitis infection, including hepatitis B and Hepatitis C, 
represent the primary caused of liver fibrosis. If left untreated fibrosis can progress to 
cirrhosis, ultimately leading to liver failure and possibility of death. A major clinical 
problem facing medical community is how to best evaluate and manage the increasing 
numbers of patients infected with viral hepatitis especially Hepatitis C. According to the 
latest consensus conference liver biopsy is still recommended in most patients. Liver 
biopsy is considered as a gold standard technique because it confum clinical diagnosis, 
assess the severity of necroinflammatory activities and fibrosis, evaluate possible 
concomitant disease process and guides therapeutic interventions. ( Aturo A. Bravo et al, 
2001) 
However, liver biopsy is an invasive and expensive method, and can have the 
remote risks of life threatening complications. Moreover the accuracy of assessing liver 
fibrosis has also been questioned. ( Aturo A. Bravo et al, 2001) 
1.2 Limitation of Liver Biopsy 
Limitation Due To Sampling Error 
Regev A. et al ( 2002), in their systemic review have demonstrated sampling 
errors not only in patients, with liver disease with a high degree of intrahepatic 
heterogenecity, such as billiary cirrhosis but also in patient with alcoholic or Hepatitis C 
1 
induced fibrosis and inflammation. Furthermore the well accepted 4 stages of META VIR 
score was used to stage fibrosis, about one third of the scores differed by at least one 
stage in the same patient when biopsy was taken from the right lobe compared with the 
left lobe. The similar results were obtained for grading of inflammation. (Regev A. et al, 
2002) 
1.2.1 Limitation Due To CompHcation and Contraindication 
(a) Limitation Due To Complications 
Liver biopsy is a safe procedure when it is performed by experienced operators. 
Froehlich et al (1993), noted that lower complication rate occur among physicians who 
performed more than 50 biopsies per year. Approximately 1 to 3 percent of patients 
required hospitalization for complication after liver biopsy. Sixty percent of the 
complications occur within 2 hours and 96 percent occur after 24 hours. Very 
rarely, there are possibility of intraperitoneal hemorrhage following the 
procedure and it usually becomes apparent within the first two to three hours after 
that. In addition the mortality rate after liver biopsy is approximately 1 in 10 000 
to 1 in 12 000 and it is highest among those who have malignant lesions. ( Aturo A. 
Bravo 2001) 
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(b) Limitation Due To Contraindication 
In many of the cases, liver biopsy cannot be perfonned due to certain reasons 
which include: 
i. Uncooperative patient 
ii. History of unexplained bleeding 
iii. Prothrombin time more than 3 to 5 seconds than control 
iv. Platelet count less than 50 000 per mm3 
v. Use of non steroidal anti-inflammatory drugs within 7 to 10 days 
vi. Suspected vascular tumors or echinococcal cyst in the liver 
vii. Inability to get appropriate site for biopsy. (Aturo A. Bravo 2001) 
As mentioned above, all these limitations of liver biopsy as well as 
the probability of inter-observer and intra-observer discrepancies in the assessment 
of liver histology have driven efforts for the development of accurate and reliable 
non- invasive means to assess the severity of liver lesion, and particularly of 
fibrosis. (Nikolaos V. et al 2005) 
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1.3 The Significant of Association Between Non Invasive Markers with Liver 
Fibrosis Score 
There is an increasing evidence supporting pivotal role of non invasive blood 
markers such as AL T, ALP and hylurounic acid in predicting liver fibrosis score. The 
AST and AL T were elevated in advanced liver fibrosis and a study by Chun Tao W et al 
2003 on AST and AST/ALT ratio showed that they were important predicted parameters 
of either significant fibrosis or cirrhosis. Hylurounic acid, an important component of 
extracellular matrix, appears to be a reliable marker for the noninvasive assessment of 
fibrosis. Studies showed serum hylurounic acid level were low in patients without liver 
disease, whereas the level were often high in patients with hepatic fibrosis ( Sandeep M et 
ai, 2006). In general fibrosis can be classified as wound- healing response to various 
chronic stimuli. It is characterized by deposition of extracellular matrix proteins which 
include glycoproteins, collagens and proteoglycans. Many studies have shown that, the 
hepatic stellate cell, is the primary cell- type in the liver responsible for excess collagen 
synthesis during hepatic fibrosis. The activation of the hepatic stellate cell leads to 
regulating cytokines signaling and cellular signaling pathways, these resulted in increase 
serum liver enzyme, and hepatic inflammation and there were study which found that 
activated hepatic stellate cell express both the renin- angiotensin and AT-II. This perhaps 
indicating that once angiotensin stimulated the activation of hepatic stellate cell and 
injury can be exacerbated by paracrine and autocrine signaling. Therefore by measuring 
the level of enzyme produced by the liver in response to activation of hepatic stellate cell, 
it will reflect the dynamic changes in the liver. (T. Shigeki, J.P Christopher and A.R 
Richard, 2005) 
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T. Poynard et al (2004), have used six serum biochemical markers which 
consisted of alpha 2-macroglobulin, haptoglobulin, gamma glutamyltransferase, total 
bilirubin, apolipoprotein At and alanine amino transferase and compared with the 
severity of the fibrosis stage and necroinflammatory grade in the liver. They found 
biochemical provides a more accurate ( quantitative and reproducible) picture of 
fibrogenic and necrotic events occurring within the liver than liver biopsy. 
Apart from the biomarkers mentioned above, there were studies conducted 
using other blood markers, such as JF. Yao et. al, (2003) whom had conducted animal 
studies to demonstrate the effect of aldosterone on hepatic stellate cell activation. They 
used rat hepatic stellate cell which were incubated with aldosterone or 
spironolactone, an aldosterone receptor antagonist at different concentration. They found 
the proliferation and collagen synthesis of hepatic stellate cell was enhanced by 
aldosterone and the effect was dose dependent. The higher the aldosterone dose, the more 
significant hepatic cell activation increased. In conclusion aldosterone can activate the 
hepatic stellate cell and subsequently lead to liver fibrosis. 
Recently, S. Damien et al. (2006) recruited 138 patients and the aim of this 
study was to assess the reliability of previous study done by T. Ponyard et al. in 2004, 
whereby the study combined the quantitative results of six serum biochemical markers 
in predicting liver fibrosis and activity among Hepatitis C infected patients and in their 
study they have included patients with Hepatitis C induce systemic vasculitis. In addition 
other biochemical non-invasive liver fibrosis indexes in such Hepatitis C infected 
populations were examined. more importantly 
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the presence of systemic vasculitis or non septic serum inflammation in Hepatitis C 
infected patients does not modify the high accuracy of the biochemical non-invasive 
scoring indexes, in predicting significant liver fibrosis. 
1.4 The Role of Liver Enzyme In Relation to The Liver Fibrosis or Inflammation 
1.4.1 Alanine Aminotransferase 
The enzyme is a sensitive indicator for liver damage therefore, it is a more 
reliable indicator compared to other liver enzymes. It is found primarily in the liver and 
significantly lesser amount are present in other body tissue. When liver parenchymal is 
damaged, alanine aminotransferase is released resulting in elevation in serum. Therefore, 
it is currently considered that serum ALT correlates with the degree of histological 
inflammation and necrosis of the liver cell. Furthennore, the higher the ALT level, the 
more rapid the development of cirrhosis and hepatocellular carcinoma. (Joseph A K and 
colleagues, 2005) 
1.4.2 Aspartate Aminotransferase 
The elevation of the aspartate aminotransferase is not always due to liver diseases, 
but if the elevations are more than four times of the upper limit, it is a significant 
indicator for cholestatic jaundice or infiltrative liver disease. Especially in the present of 
gamma-glutamyltransferase. This is because the enzyme rarely elevated in condition 
other than liver disease. (Daniel S P et ai, 2001) 
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1.5 The Role of Biosynthetic Function of the Liver in Liver Fibrosis 
1.5.1 Serum Albumin Level 
Serum albumin is synthesized exclusively by hepatocytes. It has long half-life, 
approximately 15 to 20 days with 4% degradation per day. Therefore it can be used as 
chronicity markers of liver disease. In hepatitis albumin levels below 3 gldL should raise 
the possibility of chronic liver disease. Hypoalbuminemia is more common in chronic 
liver disorders such as cirrhosis and usually reflects severe liver damage. (S.P Daniel et 
al, 2001) 
1.S.2 Serum Coagulation Profile 
With the exception of factor VIII, the blood clotting factors are made exclusively 
in the hepatocytes. Serum prothrombin time, which collectively measure factors II, V, 
VII and X, is useful to measure hepatic synthetic function and helpful in both the 
diagnosis and assessing the prognosis of liver disease.(G. Marc, J.H Hoofnagle, 2001) 
1.5.3 High-Density Lipoprotein(HDL) and Low Density Lipoprotein(LDL) 
Lipoprotein is complexes that transport lipid, to or from the tissue. All 
nucleated cell synthesized cholesterol but only hepatocytes can efficiently metabolize and 
excrete cholesterol from the body. Because the liver is the principal site of formation and 
clearance of lipoproteins, liver disease can profoundly affects plasma lipid level.( Daniel 
R J and Helen H H, 2001) 
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1.5.4 Serum Haptoglobulin 
Haptoglobulin is an alpha globulin that is present in high concentration in the 
serum. It is synthesized in the liver and the synthesis is decreased in patient with 
hepatocellular and increased in inflammatory state.( Franklin B H, 2005) 
1.6 The Role of Renin-angiotensin-aldosterone system ( RAAS) in Liver Fibrosis 
1.6.1 The Role of Angiotensin II (AT-II) 
The RAAS is an important contributor to the regulation of the blood pressure, 
water and salt balance and tissue growth. The major effectors of the RAAS, which is the 
angiotensin II is a powerful vasoconstrictor that triggers the release of aldosterone. In 
addition to its role in the blood pressure regulation, angiotensin II has a variety of action 
that associated with cardiovascular and renal pathology. Angiotensin II has been shown 
to contribute to vascular remodeling by activating signal transduction pathways, that 
promote cell growth inflammation and fibrosis. Daniel D A (2006) 
Recently Hitoshi Y et al 2006, had done a study on animal to look at the 
interaction between AT-II and VEGF in rat liver fibrosis development. They concluded 
that AT -II increase VEGFmRNA expression in the activated hepatic stellate cell in a time 
and is dose dependent manner. These results indicated that augmentation of the VEGF 
during liver fibrosis development was, at least partly, mediated by AT-II, and that the 
activated hepatic stellate cell was one of the VEGF-induced cells 
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1.6.2 Role of Serum Aldosterone 
Cirrhosis is frequently associated with the increase levels of aldosterone in the 
plasma and the urine and it has role in the activation of the hepatic stellate cell. 
Rombouts et al(2000) has demonstrated aldosterone had direct pro-fibrogenic effect on 
the hepatic stellate cell. They have conducted animal study by exposing rat hepatic 
stellate cell culture to high, near-physiological or physiological concentration of hormone 
and they measured a few parameters that indicate the activation of the hepatic stellate 
cell. Their data showed at pharmacological and near physiological concentrations 
enhance the synthesis of procollagen product, which indicates the activation of hepatic 
stellate cell. 
Caligiuri et al (2000) have shown that the incubation of the hepatic stellate cells 
with canrenone, an aldosterone antagonist, lead to the inhibition of a number of PDGF-
induce changes and one of it is PDGF-induce hepatic stellate cell proliferation and 
collagen type 1 synthesis. This study provide evidence indicating that anti-aldosterone 
drugs may directly act as anti-fibrogenic drugs. 
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1.7 Progression of Liver Disease in Relation to Histopathology Finding in Liver 
Biopsy 
1.7.1 Stages of Disease Progression 
Like other liver disease, Hepatitis C progresses in stages. The usual progression is 
from inflammation to fibrosis to cirrhosis. Fibrosis is the important stage in the 
development of liver cirrhosis. The amount of fibrosis is the way of assessing how 
quickly the disease appears to be progressing. (Douglas D T, 2003) 
Michiyasu Y and colleagues, 2000 showed that the stage of liver disease was 
almost linear according to the time, however, activity grade was not as linearly correlated 
as fibrosis stages. Thus, clinically relevant progression of chronic Hepatitis C would 
better estimated by the fibrosis stage than the grade of histological activity. They found 
that the median rate of fibrosis progression per year was 0.133 fibrosis per unit and three 
independent factors were associated with an increase rate of fibrosis which are: 
1. age older than 40 years old 
ii. daily alcohol consumption of 50 g or more 
iii. male sex 
IV. immune deficiency or immunosuppressive therapy. 
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1.7.2 Scoring and Grading Liver Biopsies 
Liver biopsy is a test in which small pieces of liver tissue are removed and 
examined under the microscope. The three main things that will be looked for are 
inflammation, fibrosis and cirrhosis. The biopsy report may also reveal other histological 
and pathological findings such as the presence of lymphoid nodule, damage to the small 
bile ducts, and/or the presence of fat. (Douglas D T,2003) 
The amount of the injury to the liver, will be tenn as inflammatory grade and 
fibrotic stage. There are three different methods used for scoring liver biopsy. The three 
scoring and grading systems for liver biopsies are the Original HAl ( Histology Activity 
Index), the Modified HAl and the Metavir. Each of the scoring systems based upon 
visual assessment of portal and periportal fibrosis. 
1.7.2(a) Original Histological Activity Index (HAl) 
The HAl scoring system range from 0 to 22 and fibrosis is staged as 0.1. 3 and 
4. This discontinuous scale was developed to allow for clear separation of mild from 
extensive fibrosis which has important prognostic value. The HAl system is simple and 
has been widely used. However, the intra-and inter-observer reproducibility of the HAl is 
not very good and the distinction between stages 1 and 3 may be difficult. In addition, its 
discontinuous scale complicates statistical analysis in clinical trials. (Douglas D T, 2003) 
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1.7.2(b) Modified HAl score 
The modification of the HAl scoring system was proposed by Ishak et al, 1995. 
This system is more sensitive in assessing fibrosis. Fibrosis stage is scored continuously 
from 0 to 6, which permits a better assessment or the effect of therapy on fibrosis. Ishak 
score's is better validated and gives a more accurate assessment of fibrosis.( Douglas D 
T,2003) 
1. 7.2( c) Metavir scoring system 
This system is simple. Fibrosis stages are scored continuously from 0 to 4. This 
System has been carefully validated in large group of patients with chronic Hepatitis C 
and has shown good intra* and inter* observer reproducibility. Important limitations of 
these scoring systems should be emphasized. Hepatic fibrosis may not be homogenous 
throughout the liver and liver specimen obtained by needle biopsy may not accurately 
reflect the overall average degree of fibrosis. The reliability of the assessment of fibrosis 
stage increase with the size of the liver sample. In most studies, a minimwn of 10 mm 
is required. Regardless of biopsy length, however, fibrosis may be underestimated and 
cirrhosis missed in some patients.( Douglas D T, 2003) 
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